Pre-clinical development of small-molecule catalytic pocket inhibitors that block AID/APOBEC-driven mutations in cancer development, aggression and resistance.

小分子催化口袋抑制剂的临床前开发，可阻止 AID/APOBEC 驱动的癌症发展、攻击性和耐药性突变。

• 批准号: 440917
• 负责人: King Justin J
• 金额: $ 9.83万
• 依托单位: Simon Fraser University (Burnaby, B.C.)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=440917&lang=en
• 关键词: Aid; Apobec; Cancer; Cell Culture; Enzyme; Inhibitor; Molecular Docking

Our lab studies AID/APOBEC, a family of DNA mutating enzymes involved in immunity and antiviral defense. AID's job is to mutate a few specific genes in B-cells (antibody-producing cells) to boost immune function, while APOBECs mutate viruses, such as HIV,

我们的实验室研究AID/APOBEC，一个参与免疫和抗病毒防御的DNA突变酶家族。AID的工作是使B细胞（产生抗体的细胞）中的一些特定基因突变以增强免疫功能，而APOBECs则使病毒突变，如HIV，